View Future GrowthActive Fine Chemicals 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Active Fine Chemicals 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률11.00%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Mar 2023최근 과거 실적 업데이트공시 • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updatesNew Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (৳1.78b market cap, or US$14.5m).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • May 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 20% over the past year. Minor Risk Market cap is less than US$100m (৳3.77b market cap, or US$32.1m).New Risk • Mar 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).New Risk • Dec 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Nov 16Upcoming dividend of ৳0.025 per shareEligible shareholders must have bought the stock before 20 November 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).공시 • Nov 01Active Fine Chemicals Limited Has Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Active Fine Chemicals Limited has recommended 0.25% Cash dividend (other than Sponsors and Directors) for the year ended on June 30, 2022.Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.00, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.7% over the past three years.Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Nov 22Upcoming dividend of ৳0.05 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 23 January 2022. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).Reported Earnings • Jun 24Third quarter 2021 earnings released: EPS ৳0.024 (vs ৳0.19 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ৳510.4m (up 55% from 3Q 2020). Net income: ৳5.86m (down 87% from 3Q 2020). Profit margin: 1.1% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Dec 28New 90-day high: ৳16.90The company is up 1.0% from its price of ৳16.80 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: ৳13.90The company is down 1.0% from its price of ৳14.00 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.매출 및 비용 세부 내역Active Fine Chemicals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DSE:ACTIVEFINE 매출, 비용 및 순이익 (BDT Millions)날짜매출순이익일반관리비연구개발비31 Mar 231,352-5166031 Dec 221,4431179030 Sep 221,523-25191030 Jun 221,67226261031 Mar 221,69955293031 Dec 211,82853305030 Sep 211,85394305030 Jun 211,82138247031 Mar 211,383-245207031 Dec 201,201-206198030 Sep 201,206-157194030 Jun 201,308-56195031 Mar 201,776377215031 Dec 192,115541223030 Sep 192,346671226030 Jun 192,419712228031 Mar 192,308989216031 Dec 182,224915207030 Sep 182,173846207030 Jun 182,156825200031 Mar 182,272548201031 Dec 172,225556194030 Sep 172,179558181030 Jun 172,129554170031 Mar 171,896486141031 Dec 161,837459131030 Sep 161,810457125030 Jun 161,894481133030 Sep 151,6654571050양질의 수익: ACTIVEFINE가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 ACTIVEFINE의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 ACTIVEFINE의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: ACTIVEFINE의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: ACTIVEFINE의 지난 해 수익 증가율이 Pharmaceuticals 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: ACTIVEFINE는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/03 20:46종가2026/07/02 00:00수익2023/03/31연간 수익2022/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Active Fine Chemicals Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023
Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
New Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (৳1.78b market cap, or US$14.5m).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • May 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 20% over the past year. Minor Risk Market cap is less than US$100m (৳3.77b market cap, or US$32.1m).
New Risk • Mar 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).
New Risk • Dec 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023
Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Nov 16Upcoming dividend of ৳0.025 per shareEligible shareholders must have bought the stock before 20 November 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
공시 • Nov 01Active Fine Chemicals Limited Has Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Active Fine Chemicals Limited has recommended 0.25% Cash dividend (other than Sponsors and Directors) for the year ended on June 30, 2022.
Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.00, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.7% over the past three years.
Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Nov 22Upcoming dividend of ৳0.05 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 23 January 2022. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).
Reported Earnings • Jun 24Third quarter 2021 earnings released: EPS ৳0.024 (vs ৳0.19 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ৳510.4m (up 55% from 3Q 2020). Net income: ৳5.86m (down 87% from 3Q 2020). Profit margin: 1.1% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Dec 28New 90-day high: ৳16.90The company is up 1.0% from its price of ৳16.80 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: ৳13.90The company is down 1.0% from its price of ৳14.00 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.